Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells

Korean Journal of Urology

Volumn 52, Issue 1, 2011, Pages 55-63

  Yoon, Cheol Yong ^a   Lee, Jung Sun ^a   Kim, Bo Sun ^a   Jeong, Seong Jin ^a   Hong, Sung Kyu ^a   Byun, Seok Soo ^a   Lee, Sang Eun ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

Carcinoma; Cisplatin; Gemcitabine; Sunitinib; Urinary bladder

Indexed keywords

CISPLATIN; CYCLIN B1; CYCLIN D; GEMCITABINE; PROTEIN BAD; PROTEIN BAX; PROTEIN KINASE B; SUNITINIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER SURVIVAL; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENIC ASSAY; COLONY FORMATION; CONCENTRATION RESPONSE; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; PROTEIN EXPRESSION; TREATMENT RESPONSE; WESTERN BLOTTING;

EID: 79551695108     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2011.52.1.55     Document Type: Article

References (29)

1. Fossa SD, Aass N, Ous S, Waehre H, Ilner K, Hannisdal E. Survival after curative treatment of muscle-invasive bladder cancer. Acta Oncol 1996;35(Suppl 8):59-65.
2. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602-8. (Pubitemid 46224062)
3. Witte RS, Elson P, Bono B, Knop R, Richardson RR, Dreicer R, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997;15:589-93. (Pubitemid 27074226)
4. Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006;24:3451-7. (Pubitemid 46638903)
5. Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, et al. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007;12:107-13. (Pubitemid 46143508)
6. Roskoski R Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 2007;356:323-8.
7. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24. (Pubitemid 43854967)
8. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007;25:4793-9. (Pubitemid 350086483)
9. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-6. (Pubitemid 351264362)
10. Bernardini S, Fauconnet S, Chabannes E, Henry PC, Adessi G, Bittard H. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 2001;166:1275-9. (Pubitemid 32862155)
11. Theodoropoulos VE, Lazaris AC, Kastriotis I, Spiliadi C, Theodoropoulos GE, Tsoukala V, et al. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int 2005;95:425-31. (Pubitemid 40283138)
12. Theodoropoulos VE, Lazaris A, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I, et al. Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 2004;46:200-8. (Pubitemid 38902737)
13. Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 2006;175:1245-52.
14. Wu W, Shu X, Hovsepyan H, Mosteller RD, Broek D. VEGF receptor expression and signaling in human bladder tumors. Oncogene 2003;22:3361-70. (Pubitemid 36713733)
15. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
16. Droller MJ. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. J Urol 1998;160:1932.
17. Crew JP, O'Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997;57:5281-5. (Pubitemid 27516364)
18. Chabannes E, Bernardini S, Wallerand H, Bittard H. Angiogenesis in bladder: prognosis indicator and therapeutic target. Prog Urol 2001;11:417-27. (Pubitemid 33703880)
19. Szarvas T, Jäger T, Droste F, Becker M, Kovalszky I, Romics I, et al. Serum levels of angiogenic factors and their prognostic relevance in bladder cancer. Pathol Oncol Res 2009;15:193-201.
20. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-6.
21. Silay MS, Miroglu C. Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects. Med Hypotheses 2007;69:892-5. (Pubitemid 47248111)
22. Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, et al. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clin Cancer Res 2009;15:3384-95.
23. Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, et al. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett 2009;279:74-83.
24. Cuneo KC, Geng L, Fu A, Orton D, Hallahan DE, Chakravarthy AB. SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys 2008;71:873-9. (Pubitemid 351749533)
25. Vogl UM, Berger W, Micksche M, Pirker C, Lamm W, Pichelmeyer O, et al. Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines. Cancer Lett 2009;277:218-26.
26. Tran Cao HS, Bouvet M, Kaushal S, Keleman A, Romney E, Kim G, et al. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther 2010;9:2068-78.
27. Reck M, Frickhofen N, Cedres S, Gatzemeier U, Heigener D, Fuhr HG, et al. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Lung Cancer 2010;70:180-7.
28. Bharthuar A, Pearce L, Litwin A, LeVea C, Kuvshinoff B, Iyer R. Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report. JOP 2009;10:523-7.
29. Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009;27:391-9.